Cardiovascular events after discontinuation of low-dose aspirin
- PMID: 29600025
- PMCID: PMC5863118
- DOI: 10.21037/jtd.2017.12.48
Cardiovascular events after discontinuation of low-dose aspirin
Conflict of interest statement
Conflicts of Interest: Dr. Pareek has served on the advisory board for, and received speaker honoraria from AstraZeneca; Dr. Kristensen has received speaker honoraria from Aspen, AstraZeneca, Bayer, and Bristol-Myers Squibb/Pfizer; Dr. Grove has received speaker honoraria from AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, and Pfizer and has previously participated in advisory board meetings for AstraZeneca, Bayer, Boehringer Ingelheim, and Bristol-Myers Squibb.
Comment on
-
Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study.Circulation. 2017 Sep 26;136(13):1183-1192. doi: 10.1161/CIRCULATIONAHA.117.028321. Circulation. 2017. PMID: 28947478
References
-
- Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349-60. - PubMed
-
- Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-7. 10.1161/01.CIR.0000091201.39590.CB - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources